课件：糖尿病新药.pptVIP

* Key Points 2相糖尿病患者心血管事件发生率高。 艾塞那肽长期治疗可以获得显著的血糖和血压改善，提示艾塞那肽长期治疗糖外获益显著。 Notes 在艾塞那肽开放标签延伸研究中，前30周分别接受安慰剂、艾塞那肽5ug、艾塞那肽10ug组30周后都接受艾塞那肽10ug治疗。 3.5年时，艾塞那肽组较安慰剂组脂代谢与血压显著改善，TG降低12%，LDL降低6%，TC降低5%，HDL增加24%，有统计学意义；同时SBP降低2%，DBP降低4%，有统计学意义。 CITATIONKlonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24:275-286. SEEpg 275 2nd column 1st paragraph and pg 280 1st column 2nd paragraph (for slide data and DISCUSSION) DISCUSSION In a subset of exenatide-treated patients who completed 3.5 years of treatment, improvements in triglycerides, LDL-C, TC, and HDL-C were noted Mean percentage changes from baseline were: triglycerides -12%, LDL-C -6%, TC -5%, and HDL-C 24% Although 25% of subjects who lost the most weight had the greatest improvements in triglycerides and HDL-C, overall there was a minimal correlation between weight change and serum lipid change BACKGROUND Patients with T2D treated with MET and/or SFU were randomised to receive placebo or exenatide in the original placebo-controlled, double-blind, Phase 3, randomised trials and received exenatide in the subsequent open-label extensions At the time of this analysis, all patients (N=151) had received 3.5 years of exposure to exenatide * Key points 2型糖尿病，肥胖和NAFLD常常共同存在 ALT升高可以提示NAFLD 艾塞那肽在控制血糖的同时降低ALT，显示出显著的糖外获益。 Notes 在艾塞那肽开放标签延伸研究中，前30周分别接受安慰剂、艾塞那肽5ug、艾塞那肽10ug组30周后都接受艾塞那肽10ug治疗。 3.5年时，ALT升高组ALT显著降低 * * Key Points 艾塞那肽治疗亚洲患者，16周时较安慰剂组HbA1c和体重都显著降低 这与之前AMIGO研究中的结果相似，证明艾塞那肽在亚裔患者中同样有效。 背景： 一项16周，随机，双盲，安慰剂对照研究。466例亚洲患者随机接受艾塞那肽或安慰剂治疗。主要研究目标是治疗终点时HbA1c的降低 * Notes： 艾塞那肽治疗亚裔患者，16周时66%的患者血糖和体重都降低 背景： 一项16周，随机，双盲，安慰剂对照研究。466例亚裔患者随机接受艾塞那肽或安慰剂治疗。主要研究目标是治疗终点时HbA1c的降低 * CITATIONKlonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at leas